Cardiovascular events, mortality, early retirement and costs in >50 000 persons with chronic heart failure in Sweden.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Oxford] : John Wiley & Sons Ltd on behalf of the European Society of Cardiology, [2014]-
    • Subject Terms:
      Heart Failure*/epidemiology ; Heart Failure*/therapy ; Myocardial Infarction* ; Stroke*/epidemiology; Humans ; Female ; Aged ; Male ; Health Care Costs ; Retirement ; Sweden/epidemiology ; Chronic Disease
    • Abstract:
      Aims: We aimed to examine cardiovascular events (stroke and myocardial infarction [MI]), mortality, early retirement and economic costs over 5 years in people with chronic heart failure (CHF) and matched controls in Sweden.
      Methods and Results: Individuals (aged ≥16 years) living in Sweden on 1 January 2012 were identified in an existing database. Individuals with CHF were propensity score matched to controls without CHF by birth year, sex and educational status. We analysed risks of stroke, MI, mortality and early retirement, and compared direct costs (inpatient care, outpatient care and drug costs) and indirect costs (work absence). After matching, there were 53 520 individuals in each cohort. In each cohort, mean age was 69.0 years (standard deviation 8.2), and 29.7% of individuals were women. People with CHF were significantly more likely than controls to experience stroke (hazard ratio 1.46 [95% confidence interval 1.38-1.56]) and MI (1.61 [1.51-1.71]). All-cause mortality was nearly three-fold higher (2.89 [2.80-2.98]) and the likelihood of early retirement was more than three-fold higher (3.69 [3.08-4.42]). Total mean annual costs per person were €9663 (standard error 38) for people with CHF, of which 53% were direct costs, and €2845 (standard error 19) for controls, of which 40% were direct costs. In people with CHF, inpatient costs comprised 78% of total annual mean direct costs over follow-up, outpatient costs contributed 15% and drug costs contributed 8%. In controls, the corresponding proportions were 71%, 18% and 11%.
      Conclusions: CHF has a considerable impact on the risk of cardiovascular events and death, early retirement and economic costs. Inpatient admissions and work absence are major contributors to economic costs.
      (© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
    • References:
      Eur J Heart Fail. 2016 Jul;18(7):744-58. (PMID: 27358242)
      Eur J Prev Cardiol. 2019 Jul;26(11):1150-1157. (PMID: 30955367)
      Aging Ment Health. 2015;19(5):381-9. (PMID: 24946236)
      Int J Cardiol. 2015 Dec;201 Suppl 1:S1-7. (PMID: 26747389)
      J Med Econ. 2012;15(5):925-37. (PMID: 22502902)
      Eur J Heart Fail. 2014 Jul;16(7):729-36. (PMID: 24806352)
      Am J Med Sci. 2020 May;359(5):257-265. (PMID: 32265010)
      Diabetologia. 2020 Dec;63(12):2582-2594. (PMID: 32968866)
      Handb Exp Pharmacol. 2017;243:35-66. (PMID: 28382470)
      BMC Cardiovasc Disord. 2018 May 2;18(1):74. (PMID: 29716540)
      BMC Cardiovasc Disord. 2016 Nov 10;16(1):215. (PMID: 27832754)
      Cardiovasc Diagn Ther. 2021 Feb;11(1):254-262. (PMID: 33708497)
      Dtsch Med Wochenschr. 2010 Apr;135(13):633-8. (PMID: 20333603)
      ESC Heart Fail. 2024 Feb;11(1):54-64. (PMID: 37814495)
      Eur J Heart Fail. 2019 Dec;21(12):1526-1531. (PMID: 31359583)
      Circulation. 2016 Oct 4;134(14):999-1009. (PMID: 27507406)
      Circ Res. 2013 Aug 30;113(6):646-59. (PMID: 23989710)
      Eur J Heart Fail. 2014 Jul;16(7):772-7. (PMID: 24863953)
      J Neurol Sci. 2020 Mar 15;410:116643. (PMID: 31927342)
      Int J Cardiol. 2014 Feb 15;171(3):368-76. (PMID: 24398230)
      Diabetes Obes Metab. 2020 Sep;22(9):1586-1597. (PMID: 32329136)
      Int J Cardiol. 2012 May 3;156(3):323-5. (PMID: 22373485)
      Inflamm Bowel Dis. 2016 Jul;22(7):1679-87. (PMID: 27206016)
      Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. (PMID: 35150240)
      BMJ Open. 2021 Oct 19;11(10):e053806. (PMID: 34667015)
      Eur J Heart Fail. 2016 Mar;18(3):242-52. (PMID: 26727047)
      ESC Heart Fail. 2022 Feb;9(1):555-563. (PMID: 34837891)
      Circ Cardiovasc Qual Outcomes. 2011 Jan 1;4(1):68-75. (PMID: 21139091)
    • Grant Information:
      Novo Nordisk A/S
    • Contributed Indexing:
      Keywords: Absenteeism; Burden of illness; Chronic heart failure; Direct costs; Indirect costs; Mortality
    • Publication Date:
      Date Created: 20231010 Date Completed: 20240124 Latest Revision: 20240125
    • Publication Date:
      20240125
    • Accession Number:
      PMC10804168
    • Accession Number:
      10.1002/ehf2.14480
    • Accession Number:
      37814495